title: Relationship between body surface area and ALT normalization after long-term lamivudine treatment.
abstract: OBJECTIVE
  To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation.
  
  
  METHODS
  We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed.
  
  
  RESULTS
  For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels.
  
  
  CONCLUSIONS
  BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.
authors.affiliation: Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-5282, Japan. nakamuta@intmed3.med.kyushu-u.ac.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakamuta
authors.forename: Shusuke
authors.initials: S
authors.lastname: Morizono
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tanabe
authors.forename: Eiji
authors.initials: E
authors.lastname: Kajiwara
authors.forename: Junya
authors.initials: J
authors.lastname: Shimono
authors.forename: Akihide
authors.initials: A
authors.lastname: Masumoto
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Maruyama
authors.forename: Norihiro
authors.initials: N
authors.lastname: Furusyo
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Nomura
authors.forename: Hironori
authors.initials: H
authors.lastname: Sakai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takahashi
authors.forename: Koichi
authors.initials: K
authors.lastname: Azuma
authors.forename: Shinji
authors.initials: S
authors.lastname: Shimoda
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kotoh
authors.forename: Munechika
authors.initials: M
authors.lastname: Enjoji
authors.forename: Jun
authors.initials: J
authors.lastname: Hayashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood*; D001830:Body Surface Area; D003627:Data Interpretation, Statistical; D005260:Female; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000410:Alanine Transaminase